Ark Biopharmaceutical
Ark Biopharmaceutical (爱科百发, Ark Biosciences) is a Shanghai-based clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for respiratory diseases and pediatric conditions. Its pipeline includes AK0529 (ziresovir) for respiratory syncytial virus (RSV) infection, AK0901 for ADHD, AK3280 for idiopathic pulmonary fibrosis, AK0610 for RSV prevention, and AK0705 for COPD. The company is a portfolio company of Qiming Venture Partners and was added to the API Evangelist network as a stub for enrichment. As a drug-development company it publishes a corporate website, R&D pipeline, and news center, but exposes no public developer platform, API, or technical integration surface at this time.
Ark Biopharmaceutical is profiled on the APIs.io network. Tagged areas include Company, Biopharmaceutical, Pharmaceuticals, Biotechnology, and Drug Development.
Ark Biopharmaceutical’s developer surface includes engineering blog and 3 more developer resources.
Kin Score
Security Posture 1
Authentication, domain security, vulnerability disclosure, and trust-center signals.
Resources
Access & Security 1
Authentication, authorization, and security posture
Company 3
The organization behind the API